Termination of LitigationTermination of Litigation • January 8th, 2008 • King Pharmaceuticals Inc • Pharmaceutical preparations • New York
Pursuant to Rule 41(a)(1)(ii), Fed. R. Civ. P., IT IS HEREBY STIPULATED AND AGREED, by and between the parties, through their undersigned counsel of record, that this action be and hereby is voluntarily dismissed in its entirety without prejudice, including all claims and counterclaims by and against all parties arising out of the pleadings in this action. Each party shall bear its own attorneys’ fees and costs.
METAXALONE 800 mg PRODUCT AGREEMENTProduct Agreement • January 8th, 2008 • King Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS METAXALONE 800 mg PRODUCT AGREEMENT (“Agreement”), dated as of January 2, 2008 (the “Effective Date”), is made by and among King Pharmaceuticals, Inc. (“King Pharma”), a Tennessee corporation having its principal place of business at 501 Fifth Street, Bristol, Tennessee 37620, King Pharmaceuticals Research and Development, Inc. (“King R&D”), a Delaware corporation having its principal place of business at 4000 CentreGreen Way, Suite 300, Cary, North Carolina and CorePharma LLC, a New Jersey limited liability company having its principal place of business at 215 Wood Avenue, Middlesex, New Jersey 08846 (“Core”).
